AcuityMD, the MedTech Intelligence Platform, has been named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation. The list has a strong track record: more than 100 startups named in the past 10 years have since become unicorns.
This recognition highlights AcuityMD’s rapid growth and innovation since its inception in 2019. Over the past year, the company signed its 300th customer, launched two innovative products, and doubled its staff, including the addition of Brian Collins as Chief Product Officer. Collins brings decades of product leadership experience from Salesforce, Demandware, Oracle, and other category-defining companies.
Following a $45 million Series B funding round in 2024, AcuityMD’s total funding now exceeds $83 million. As the global medical devices market is expected to expand from about $542 billion in 2024 to $886 billion by 2032, AcuityMD is well-positioned to capitalize on this growth trajectory.
“Being named on the Forbes list is a testament to our team’s dedication to customers and commitment to our mission: to accelerate the adoption of cutting-edge medical technologies,” said Mike Monovoukas, CEO and co-founder of AcuityMD. “While we are grateful to be recognized, we remain grounded in the work ahead to help our customers bring breakthrough medical innovation to more patients.”
AcuityMD combines real-world healthcare data, AI-powered insights, and intuitive workflows to give MedTech companies the information they need to grow market share and get their innovative technology to more patients faster. Its intelligence platform is trusted by leading MedTech companies, including Becton Dickinson, Teleflex, and Olympus. AcuityMD was also recently named to Newsweek’s “America’s Greatest Startup Workplaces 2025.”
The Forbes’ “Next Billion-Dollar Startups” list, now in its 11th year, is a solid indicator of startup success. Of the list’s 250 alumni, 140, or 56%, became unicorns, including DoorDash, Figma and Anduril.
“AcuityMD stands out because the company is applying AI to deliver real ROI in the complex, underserved MedTech market," said Logan Bartlett, Managing Director at Redpoint, a venture capital firm focused on investments in seed, early and growth-stage companies. "It’s exactly the kind of business we believe will define the future of AI-powered vertical software.”
Forbes Methodology
The selection process for Forbes’ Next Billion-Dollar Startups list is grounded in a data-driven methodology that combines company-submitted information, input from venture capital firms, select third-party data, and historical trends. To qualify, companies must be private, venture-backed, based in the United States, and have a valuation under $1 billion at the time of consideration. The evaluation model prioritizes key quantitative metrics such as valuation and revenue, which carry the greatest weight, alongside other indicators including user or customer count and employee headcount. Each applicant is assessed within this multi-factor framework to identify startups demonstrating strong growth, scalability, and the potential to surpass the billion-dollar threshold in the near future. More on the methodology can be found here.
About AcuityMD
AcuityMD is the MedTech Intelligence Platform trusted by more than 300 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology.
